Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-06-12

Clinical Trial Update: A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial update on dulaglutide (LY2189265) for type 2 diabetes completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dulaglutide (dulaglutide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2020-06-12